Tracing the development of acute myeloid leukemia in CBL syndrome

Blood

Volumn 123, Issue 12, 2014, Pages 1883-1886

  Becker, Heiko ^a   Yoshida, Kenichi ^b,c   Blagitko Dorfs, Nadja ^a   Claus, Rainer ^a   Pantic, Milena ^a   Abdelkarim, Mahmoud ^a   Niemöller, Christoph ^a   Greil, Christine ^a   Hackanson, Björn ^a   Shiraishi, Yuichi ^d   Chiba, Kenichi ^d   Tanaka, Hiroko ^d   Miyano, Satoru ^d   Döhner, Konstanze ^e   Schnittger, Susanne ^f   Henneke, Philipp ^a   Niemeyer, Charlotte M ^a   Flotho, Christian ^a   Pfeifer, Dietmar ^a   Ogawa, Seishi ^b,c   Lübbert, Michael ^a   more..

^a UNIVERSITY OF FREIBURG   (Germany)

^b KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

^e UNIVERSITY OF ULM   (Germany)

^f MLL MUNICH LEUKEMIA LABORATORY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; DASATINIB;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ALLELE; ARTICLE; BLOOD CELL COUNT; BONE MARROW; CANCER CHEMOTHERAPY; CAND1 GENE; CASE REPORT; CBL SYNDROME; CHILDHOOD LEUKEMIA; CHROMOSOME; CODON; CONSOLIDATION CHEMOTHERAPY; DEVELOPMENT; DOCK6 GENE; DRUG MEGADOSE; EXOME; GENE AMPLIFICATION; GENE DOSAGE; GENE MUTATION; GENE SEQUENCE; GENETIC DISORDER; GRANULOCYTE; HEMATOPOIESIS; HETEROZYGOSITY LOSS; HOMOZYGOTE; HUMAN; JUVENILE MYELOMONOCYTIC LEUKEMIA; LEUKEMIA REMISSION; MALE; NID2 GENE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PTPRT GENE; WILD TYPE;

ADULT; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 11; GENE AMPLIFICATION; GERM-LINE MUTATION; HEMATOLOGIC DISEASES; HEMATOPOIESIS; HOMOZYGOTE; HUMANS; LEUKEMIA, MYELOID, ACUTE; LOSS OF HETEROZYGOSITY; MALE; PROTO-ONCOGENE PROTEINS C-CBL; SPHEROCYTOSIS, HEREDITARY; SYNDROME;

EID: 84897535246     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-10-533844     Document Type: Article

References (25)

1. Juliusson G, Antunovic P, Derolf A, et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood. 2009;113(18):4179-4187.
2. Sanada M, Suzuki T, Shih LY, et al. Gain-offunction of mutated C-CBL tumour suppressor in myeloid neoplasms. Nature. 2009;460(7257):904-908.
3. Loh ML, Sakai DS, Flotho C, et al. Mutations in CBL occur frequently in juvenile myelomonocytic leukemia. Blood. 2009;114(9):1859-1863.
4. Makishima H, Cazzolli H, Szpurka H, et al. Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies. J Clin Oncol. 2009;27(36):6109-6116.
5. Pérez B, Kosmider O, Cassinat B, et al. Genetic typing of CBL, ASXL1, RUNX1, TET2 and JAK2 in juvenile myelomonocytic leukaemia reveals a genetic profile distinct from chronic myelomonocytic leukaemia. Br J Haematol. 2010;151(5):460-468.
6. Kohlmann A, Grossmann V, Klein HU, et al. Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1. J Clin Oncol. 2010;28(24):3858-3865.
7. Itzykson R, Kosmider O, Renneville A, et al. Prognostic score including gene mutations in chronic myelomonocytic leukemia. J Clin Oncol. 2013;31(19):2428-2436.
8. Niemeyer CM, Kang MW, Shin DH, et al. Germline CBL mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukemia. Nat Genet. 2010;42(9):794-800.
9. Martinelli S, De Luca A, Stellacci E, et al. Heterozygous germline mutations in the CBL tumor-suppressor gene cause a Noonan syndrome-like phenotype. Am J Hum Genet. 2010;87(2):250-257.
10. Pérez B, Mechinaud F, Galambrun C, et al. Germline mutations of the CBL gene define a new genetic syndrome with predisposition to juvenile myelomonocytic leukaemia. J Med Genet. 2010;47(10):686-691.
11. Weissmann S, Alpermann T, Grossmann V, et al. Landscape of TET2 mutations in acute myeloid leukemia. Leukemia. 2012;26(5):934-942.
12. Abbas S, Rotmans G, Löwenberg B, Valk PJ. Exon 8 splice site mutations in the gene encoding the E3-ligase CBL are associated with core binding factor acute myeloid leukemias. Haematologica. 2008;93(10):1595-1597.
13. Reindl C, Quentmeier H, Petropoulos K, et al. CBL exon 8/9 mutants activate the FLT3 pathway and cluster in core binding factor/11q deletion acute myeloid leukemia/myelodysplastic syndrome subtypes. Clin Cancer Res. 2009;15(7):2238-2247.
14. Haferlach C, Dicker F, Kohlmann A, et al. AML with CBFB-MYH11 rearrangement demonstrate RAS pathway alterations in 92% of all cases including a high frequency of NF1 deletions. Leukemia. 2010;24(5):1065-1069.
15. Fröhling S, Skelin S, Liebisch C, et al. Comparison of cytogenetic and molecular cytogenetic detection of chromosome abnormalities in 240 consecutive adult patients with acute myeloid leukemia. J Clin Oncol. 2002;20(10):2480-2485. (Pubitemid 34525733)
16. Schnittger S, Weisser M, Schoch C, Hiddemann W, Haferlach T, Kern W. New score predicting for prognosis in PML-RARA+, AML1-ETO+, or CBFBMYH11+ acute myeloid leukemia based on quantification of fusion transcripts. Blood. 2003;102(8):2746-2755. (Pubitemid 37248843)
17. Döhner K, Schlenk RF, Habdank M, et al. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood. 2005;106(12):3740-3746. (Pubitemid 41739007)
18. Schnittger S, Bacher U, Alpermann T, et al. Use of CBL exon 8 and 9 mutations in diagnosis of myeloproliferative neoplasms and myelodysplastic/ myeloproliferative disorders: an analysis of 636 cases. Haematologica. 2012;97(12):1890-1894.
19. Yoshida K, Sanada M, Shiraishi Y, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature. 2011;478(7367):64-69.
20. Forbes SA, Bindal N, Bamford S, et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res. 2011;39(Database issue): D945-D950. http://www.sanger.ac.uk/cosmic. Accessed September 24, 2013.
21. Ding L, Ley TJ, Larson DE, et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature. 2012;481(7382):506-510.
22. Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368(22):2059-2074.
23. Emanuel PD, Bates LJ, Castleberry RP, Gualtieri RJ, Zuckerman KS. Selective hypersensitivity to granulocyte-macrophage colony-stimulating factor by juvenile chronic myeloid leukemia hematopoietic progenitors. Blood. 1991;77(5):925-929.
24. Strullu M, Caye A, Cassinat B, et al. In hematopoietic cells with a germline mutation of CBL, loss of heterozygosity is not a signature of juvenile myelo-monocytic leukemia. Leukemia. 2013;27(12):2404-2407.
25. Owen C, Barnett M, Fitzgibbon J. Familial myelodysplasia and acute myeloid leukaemia - a review. Br J Haematol. 2008;140(2):123-132. (Pubitemid 350265048)